COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
Budesonide study #2 of 3
4/12 Late treatment study
Yu et al., medRxiv, doi:10.1101/2021.04.10.21254672 (Preprint)
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
Source   PDF   Share   Tweet
Interim results from the PRINCIPLE trial, 751 treated with budesonide starting a median of 6 days after symptom onset, showing lower hospitalization/death, and faster recovery with treatment.

Yu et al., 4/12/2021, Randomized Controlled Trial, preprint, 24 authors.
risk of combined hospitalization/death, 17.5% lower, RR 0.83, p = 0.24, treatment 59 of 692 (8.5%), control 100 of 968 (10.3%), day 28.
risk of mechanical ventilation, 2.3% higher, RR 1.02, p = 1.00, treatment 11 of 743 (1.5%), control 11 of 760 (1.4%).
risk of ICU admission, 45.5% lower, RR 0.54, p = 0.17, treatment 9 of 735 (1.2%), control 17 of 756 (2.2%).
recovery time, 17.2% lower, relative time 0.83, p = 0.001, treatment 751, control 1028.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 3 studies
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary; multiple approaches are required to protect all people from all existing and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Submit